Rheumatology Medical News about rheumatoid arthritis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): p38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis
Cytokine, 09/03/09

Aerts NE et al. – In rheumatoid arthritis, adalimumab therapy decreases the phosphorylation of p38 MAPK except for its response to TNF/IL-1, while enhancing the production of IFN?, sugesting that p38 MAPK is not directly involved in the effect of TNF inhibition on cytokine production.

Methods

Phosphorylation of p38 MAPK was analysed flow cytometrically in peripheral blood mononuclear cells (PBMC) from healthy individuals and RA patients before and after adalimumab therapy
Cytokine production by CD3/CD28-stimulated PBMC was measured in the supernatant

Results

Despite a transient activation of p38 MAPK in response to cellular stress from the cell separation, a significant decrease of spontaneous p38 MAPK phosphorylation was observed after adalimumab, compared to RA patients with active disease
Brief stimulation with TNF?/IL-1? significantly activated p38 MAPK after but not before adalimumab therapy
In CD3/CD28-stimulated PBMC, significantly less p38 MAPK activation and increased IFN? production were observed after adalimumab therapy

<< Previous
Diagnostic and prognostic value of antibodies against chimeric...

Next >>
Total shoulder replacement in rheumatoid disease